SULFADIAZINE


Trade Names	SULFADIAZINE
Synonyms	Adiazine Coco-diazine Diazyl NSC-35600 SSD Sildaflo Silvadene Sulfacombin Sulfadiazine Sulfadiazine (trisulfapyrimidines) Sulfapyrimidine Sulfolex Sulphadiazine Thermazene
Status
Molecule Category	Free-form
ATC	J01EC02
UNII	0N7609K889
EPA CompTox	DTXSID7044130


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SEEPANYCNGTZFQ-UHFFFAOYSA-N
Smiles	Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
InChI	InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H10N4O2S
Molecular Weight	250.28
AlogP	0.86
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	97.97
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	17.0

Pharmacology

Mechanism of Action	Action	Reference
Bacterial dihydropteroate synthase inhibitor	INHIBITOR	PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C9	-	-	-	-
Enzyme Kinase Protein Kinase Other protein kinase group Other protein kinase AUR family	-	21000	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	74

Related Entries

Environmental Exposure

Environmental Exposure Map

Countries
Bangladesch
Croatia
Czech Republic
Germany
Hungary
Romania
Slovakia
Vietnam

Cross References

Resources	Reference
ChEBI	9328
ChEMBL	CHEMBL439
DrugBank	DB00359
DrugCentral	2500
FDA SRS	0N7609K889
Human Metabolome Database	HMDB0014503
KEGG	C07658
PharmGKB	PA451539
PubChem	5215
SureChEMBL	SCHEMBL24176
ZINC	ZINC000000120319

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).